高牛磺酸 MSDSHomotaurine
Tramiprosate (200 μg/mL, 40 μg/mL, 8 μg/mL and 1.6 μg/mL; 1 hours) significantly attenuates oxygen/glucose deprivation (OGD)- or NMDA-induced injury in NGF-differentiated PC12 cells and primary cortical neurons. Tramiprosate decreases the intensity of the association between nNOS and PSD95, and Tramiprosate also inhibits the translocation of nNOS from the cytosol to the membrane.
Tramiprosate (6.25-50 mg/kg; intraperitoneal injection; once) treatment dose-dependently reduces the infarct volume after MCAO. Tramiprosate (50 mg/kg) treatment shows a significant neurological functional recovery.